Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial
G. Jenkins (Nottingham, United Kingdom), I. Noth (Charlottesville, Virginia, United States of America), M. Selman (Mexico City, Mexico), V. Cottin (Lyon, France), Y. Nishioka (Tokushima, Japan), J. Song (Seoul, Republic of Korea), A. Prasse (Hannover, Germany), E. White (Ann Arbor, Michigan, United States of America), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein,, Germany), S. Stowasser (Ingelheim am Rhein,, Germany), T. Maher (London, United Kingdom)
Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Jenkins (Nottingham, United Kingdom), I. Noth (Charlottesville, Virginia, United States of America), M. Selman (Mexico City, Mexico), V. Cottin (Lyon, France), Y. Nishioka (Tokushima, Japan), J. Song (Seoul, Republic of Korea), A. Prasse (Hannover, Germany), E. White (Ann Arbor, Michigan, United States of America), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein,, Germany), S. Stowasser (Ingelheim am Rhein,, Germany), T. Maher (London, United Kingdom). Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial. 5187
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: